Gilead Sciences Inc. (NASDAQ:GILD)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Group in a research note issued to investors on Tuesday.
GILD has been the subject of a number of other reports. Barclays PLC reissued an “overweight” rating on shares of Gilead Sciences in a research note on Thursday, July 28th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, October 3rd. Bank of America Corp. reissued a “neutral” rating and issued a $100.00 target price on shares of Gilead Sciences in a research note on Sunday, September 25th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Finally, Leerink Swann set a $112.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, September 22nd. Ten research analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $97.90.
Gilead Sciences (NASDAQ:GILD) opened at 75.44 on Tuesday. The stock’s 50 day moving average price is $74.56 and its 200-day moving average price is $80.20. The firm has a market cap of $99.39 billion, a price-to-earnings ratio of 6.98 and a beta of 1.25. Gilead Sciences has a one year low of $71.39 and a one year high of $108.31.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing analysts’ consensus estimates of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The company had revenue of $7.40 billion for the quarter, compared to analyst estimates of $7.47 billion. During the same period last year, the firm earned $3.22 earnings per share. The firm’s revenue for the quarter was down 9.6% on a year-over-year basis. Analysts forecast that Gilead Sciences will post $11.47 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Stockholders of record on Thursday, December 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date is Tuesday, December 13th. Gilead Sciences’s payout ratio is 17.44%.
In other news, insider John C. Martin sold 100,000 shares of the stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $77.48, for a total value of $7,748,000.00. Following the completion of the transaction, the insider now directly owns 3,287,810 shares in the company, valued at approximately $254,739,518.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John W. Madigan sold 105,000 shares of the stock in a transaction on Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the transaction, the director now owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital Research Global Investors boosted its position in shares of Gilead Sciences by 9.7% in the third quarter. Capital Research Global Investors now owns 27,886,530 shares of the biopharmaceutical company’s stock worth $2,206,382,000 after buying an additional 2,474,271 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 26,786,930 shares of the biopharmaceutical company’s stock valued at $2,119,382,000 after buying an additional 169,701 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Gilead Sciences by 6.8% in the third quarter. BlackRock Fund Advisors now owns 26,032,555 shares of the biopharmaceutical company’s stock valued at $2,059,696,000 after buying an additional 1,663,268 shares in the last quarter. Capital World Investors raised its position in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Finally, Temasek Holdings Private Ltd raised its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock valued at $1,270,471,000 after buying an additional 1,035,592 shares in the last quarter. Institutional investors own 76.65% of the company’s stock.
Gilead Sciences Company Profile